Table 1 Baseline characteristics of the study population
Variable | Total number of CT* scans (n = 211) | No prophylaxis (n = 163) | Prophylaxis (n = 48) | p value |
|---|---|---|---|---|
Male gender | 125 (59.2 %) | 99 (60.7 %) | 26 (54.2 %) | 0.42 |
Age (years) | 65.3 (12.5) | 64.3 (12.6) | 68.6 (11.5) | 0.04 |
Baseline sCr (μmol/L) | 77.7 (71.5) | 73.0 (53.0) | 104.5 (134.0) | < 0.01 |
Baseline GFR$ (mL/min) | 68.6 (37.9) | 73.6 (38.4) | 51.8 (31.0) | < 0.01 |
§APACHE II score | 20.4 (8.3) | 20.5 (8.5) | 20.0 (7.5) | 0.70 |
APACHE IV score | 79.5 (30.1) | 78.6 (31.6) | 82.5 (24.4) | 0.43 |
Predicted in-hospital mortality (%) | 35.6 % (24.2 %) | 34.4 (25.0) | 39.8 (21.2 %) | 0.18 |
SOFA# day 1 | 5.0 (6.0) | 6.5 (5.0) | 5.0 (5.0) | 0.07 |
SOFA day 4 | 6.0 (5.0) | 6.0 (7.0) | 4.0 (5.0) | 0.02 |
Comorbidities | ||||
Diabetes | 32 (15.2 %) | 31 (19.0 %) | 1 (2.1 %) | < 0.01 |
Heart failure | 11 (5.2 %) | 6 (3.7 %) | 5 (10.4 %) | 0.09 |
Sepsis | 56 (26.5 %) | 42 (25.8 %) | 14 (29.2 %) | 0.64 |
Haemoglobin < 6 (mmol/L) | 57 (27.0 %) | 42 (25.8 %) | 15 (31.3 %) | 0.45 |
Fluid balance | 2529 (4701) | 2401 (4639) | 3123 (5695) | 0.54 |
Patients receiving norepinephrine | 54 (25.6 %) | 43 (26.4 %) | 11 (22.9 %) | 0.63 |
Patients receiving aminoglycosides | 12 (5.7 %) | 10 (6.1 %) | 2 (4.2 %) | 1.00 |